Vericel (NASDAQ:VCEL) Upgraded by ValuEngine to “Buy”

Vericel (NASDAQ:VCEL) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Monday, ValuEngine reports.

VCEL has been the topic of several other research reports. HC Wainwright began coverage on Vericel in a research note on Wednesday, October 9th. They set a “buy” rating and a $19.00 target price on the stock. BTIG Research set a $24.00 target price on Vericel and gave the company a “buy” rating in a research note on Monday, August 12th. BidaskClub raised Vericel from a “hold” rating to a “buy” rating in a research note on Tuesday, October 29th. Zacks Investment Research reissued a “buy” rating and issued a $16.00 price objective on shares of Vericel in a research note on Saturday, October 12th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Vericel in a research note on Tuesday, November 5th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $21.78.

Shares of Vericel stock opened at $18.45 on Monday. The business’s fifty day moving average price is $16.75 and its two-hundred day moving average price is $16.99. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.93 and a quick ratio of 6.48. The company has a market capitalization of $829.08 million, a P/E ratio of -131.79 and a beta of 2.66. Vericel has a 1-year low of $13.40 and a 1-year high of $21.00.

Vericel (NASDAQ:VCEL) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.09. The firm had revenue of $30.50 million for the quarter, compared to the consensus estimate of $26.84 million. Vericel had a positive return on equity of 3.66% and a negative net margin of 12.68%. The firm’s revenue for the quarter was up 35.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.02) EPS. On average, research analysts expect that Vericel will post 0.16 earnings per share for the current fiscal year.

In other news, CEO Dominick Colangelo sold 58,125 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $14.88, for a total value of $864,900.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Michael Halpin sold 15,047 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $18.53, for a total value of $278,820.91. The disclosure for this sale can be found here. 4.50% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of VCEL. Emerald Advisers LLC grew its holdings in shares of Vericel by 86.8% in the 2nd quarter. Emerald Advisers LLC now owns 778,233 shares of the biotechnology company’s stock worth $14,701,000 after acquiring an additional 361,636 shares during the last quarter. Emerald Mutual Fund Advisers Trust grew its holdings in shares of Vericel by 31.0% in the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 718,359 shares of the biotechnology company’s stock worth $13,570,000 after acquiring an additional 169,999 shares during the last quarter. Allianz Asset Management GmbH grew its holdings in shares of Vericel by 92.8% in the 2nd quarter. Allianz Asset Management GmbH now owns 446,246 shares of the biotechnology company’s stock worth $8,430,000 after acquiring an additional 214,754 shares during the last quarter. Advisory Services Network LLC grew its holdings in shares of Vericel by 100.0% in the 2nd quarter. Advisory Services Network LLC now owns 3,000 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,500 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Vericel in the 3rd quarter worth $1,594,000. 86.86% of the stock is currently owned by institutional investors.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

Further Reading: Stock Selection – What is cash flow?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.